InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Arthur David J., Chief Executive Officer. Director active across 1 company, notably Salarius Pharmaceuticals, Inc.. Cumulatively, 14 disclosures have been logged. Split: 4 buys · 0 sell. Total volume traded: €53k. History available since 3 May 2021. The latest transaction was disclosed on 13 February 2023 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
14,300 shares0Common StockSEC:0001615219-23-000023:0
20,000 shares0Common StockSEC:0001615219-23-000002:0
2,693 shares@ US$1.7344.4% of flowCommon StockSEC:0001615219-22-000155:0
10,000 shares@ US$1.73416.2% of flowCommon StockSEC:0001615219-22-000144:0
10,000 shares@ US$1.73416.2% of flowCommon StockSEC:0001615219-22-000142:0
3,400 shares@ US$0.180.8% of flowCommon StockSEC:0001615219-22-000087:0
Ideal exit: 20 Feb 2023 (T+270)
10,000 shares@ US$0.18632.6% of flowCommon StockSEC:0001615219-22-000069:0
139,488 shares@ US$0.39171.2% of flowCommon StockSEC:0001615219-22-000018:0
Ideal exit: 28 Nov 2022 (T+270)
7,939 shares@ US$0.71876.2% of flowCommon StockSEC:0001615219-21-000096
7,939 shares@ US$0.7187.1% of flowCommon StockSEC:0001615219-21-000096:0
2,000 shares@ US$0.8992.2% of flowCommon StockSEC:0001615219-21-000087:0
Ideal exit: 14 May 2022 (T+270)
2,000 shares@ US$0.8991.4% of flowCommon StockSEC:0001615219-21-000087
Ideal exit: 14 May 2022 (T+270)
9,822 sharesCommon StockSEC:0001615219-21-000040
9,822 shares@ US$0.5676.7% of flowCommon StockSEC:0001615219-21-000040:0
14 of 14 declarations
About Arthur David J.
David J. Arthur is the Chief Executive Officer of Salarius Pharmaceuticals, Inc. He oversees the company's operations and is responsible for implementing growth strategies. With a strong background in the pharmaceutical sector, he leads efforts to develop innovative treatments. His leadership is essential in positioning Salarius as a key player in the healthcare field.
